Join
Live feed
·
PRReleasevia Quantisnow
Seres Therapeutics Inc. logo

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

ByQuantisnow·Wall Street's wire, on your screen.
MCRB· Seres Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MCRB (Seres Therapeutics Inc.) and more on Quantisnow.